Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro and In Vivo Preclinical Studies
Synthetic antigen-encoding mRNA is increasingly exploited as a tool for delivery of genetic information of complete antigens into professional antigen presenting dendritic cells for HLA haplotype-independent antigen-specific vaccination against cancer. Two strategies for mRNA-based antitumor vaccination have emerged into the clinical setting. One is transfection of autologous dendritic cells with synthetic mRNA for adoptive transfer into the patient. The other is direct injection of naked synthetic mRNA. Both methods have proven to be feasible and safe and to elicit antigen-specific immune responses. The design of novel synthetic vaccines employing synthetic mRNA requires further in-depth investigation of its bioavailability and immune pharmacology. This chapter summarizes the state-of-art in this field and describes methods elementary for preclinical studies of mRNA-based antitumor vaccine protocols.
- Target Preparation for Genotyping Specific Genes or Gene Segments
- Isolation of YAC Ends by Plasmid Rescue
- Experimental Strategies in Efficient Transfection of Mammalian Cells: Calcium Phosphate and DEAE-Dextran
- Molecular Mapping and Breeding with Microsatellite Markers
- Coupling of DNA Helicase Function to DNA Strand Exchange Activity
- Computational Studies of Imprinted Genes
- Biolistic Transformation of Caenorhabditis elegans
- Mutation Detection Using RT-PCR-RFLP
- Rat Genomics Applied to Psychiatric Research
- Preparation and Use of 32P-Labeled Single-Locus VNTR Probes in Identity Testing